The telehealth company Hims & Hers put out a Super Bowl ad that skimped on clarifying that its compounded semaglutide ...

Jim Cramer, the host of Mad Money, recently took a deep dive into the challenges facing the consumer packaged goods sector, ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be short-lived deal ...

As Ozempic use rises, some patients report unexpected nasal symptoms, prompting researchers to investigate this new and unusual side effect.

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Hershey's current stock decline is due to high cocoa prices, but historical trends suggest recovery once prices normalize.